BioWorld

Dec. 2, 2009

Protalix: $115M Gaucher's Deal with Pfizer is Just the Beginning

Shares of Protalix BioTherapeutics Inc. dipped 13.7 percent on Tuesday after the biotech unveiled a $115 million profit-sharing deal with Pfizer Inc. for Gaucher's disease drug Uplyso (taliglucerase alfa). (BioWorld Today) Read More

Synagis, Synergy: Trellis Getting $338M In RSV MedImmune Deal

Forma Moving from Platform to Pipeline with $25M Series B

NewCo News: Syntiron Dressing Up Turkey Vaccine; Possible Human Use

Bayer Schering Bites on BiTE Option for Micromet Antibody

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for March 19, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...